Allogeneic Transplantation for CML

摘要: The management of CML has changed dramatically over the past 5–7 years. development specific tyrosine kinase inhibitor, imatinib, resulted in incidences cytogenetic and molecular response that far exceed those achieved with interferon. median duration survival is predicted to increase role allogeneic transplantation correspondingly decreased. However, technology allografting also progressed developments typing methodology infection have an improvement outcome unrelated transplants. imatinib era coincided reduced intensity conditioning regimens early results suggest this effective strategy associated low transplant-related mortality. This chapter summarizes data on prognostic factors for both disease- outcomes outlines current indications transplant CML. These will continue evolve. Although no longer initial therapy majority patients, it remains highest probability achieving a remission curing disease. As such play